Detalhe da pesquisa
1.
Neratinib in advanced HER2-positive breast cancer: experience from the royal Marsden hospital.
Breast Cancer Res Treat
; 195(3): 333-340, 2022 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-35976513
2.
Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
Br J Cancer
; 125(2): 299-304, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34017085
3.
Systemic Therapies for HER2-Positive Advanced Breast Cancer.
Cancers (Basel)
; 16(1)2023 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-38201451
4.
Vinorelbine After Prior Treatment With Eribulin for Advanced Breast Cancer: A Single-Centre Experience Suggesting Cross-Resistance.
Clin Breast Cancer
; 22(7): e825-e831, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35840514
5.
Targeting angiogenesis in esophagogastric adenocarcinoma.
Oncologist
; 16(6): 844-58, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21632459
6.
Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.
Breast Cancer (Dove Med Press)
; 13: 361-381, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079368
7.
Heterogeneous HER2 Amplification-a New Clinical Category of HER2-Positive Breast Cancer?
Cancer Discov
; 11(10): 2369-2371, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34598949
8.
Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Cancer Discov
; 11(1): 92-107, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32958578
9.
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Clin Cancer Res
; 26(3): 608-622, 2020 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31591187
10.
To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.
Clin Cancer Res
; 25(1): 21-28, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30224338
11.
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
N Engl J Med
; 362(9): 858-9, 2010 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-20200397
12.
An evaluation of FIGO 2000: the first 5 years.
J Reprod Med
; 53(8): 615-22, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18773627
13.
Investigational antibody-drug conjugates in clinical trials for the treatment of breast cancer.
Expert Opin Investig Drugs
; 30(8): 789-795, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34114911
14.
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
J Clin Oncol
; 34(23): 2721-7, 2016 08 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27298411
15.
Current and Future Therapies for Advanced Gastric Cancer.
Clin Colorectal Cancer
; 14(4): 239-50, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26524924
16.
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.
Therap Adv Gastroenterol
; 5(5): 301-18, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22973416
17.
De-escalating and escalating systemic therapy of early breast cancer.
Breast
; 34 Suppl 1: S5-S9, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28694014
18.
Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.
Drugs
; 71(5): 541-55, 2011 Mar 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21443280
19.
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Eur J Cancer
; 47(8): 1146-51, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21269822
20.
Trastuzumab in gastric cancer.
Eur J Cancer
; 46(11): 1949-59, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20542421